Thalidomide: An option for the pediatric patient with actinic prurigo

Actinic prurigo (AP) is an immune‐mediated photodermatosis that usually starts in childhood and is predominant among American indigenous and mestizo communities. In adults with AP, thalidomide is the treatment of choice; however, there is little information on its use in pediatric patients. We repor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric dermatology 2020-03, Vol.37 (2), p.362-365
Hauptverfasser:	Watts‐Santos, Anabella, Martinez‐Rico, Jessica Carolina, Gomez‐Flores, Minerva, Ocampo‐Candiani, Jorge, Alba‐Rojas, Erika
Format:	Artikel
Sprache:	eng
Schlagworte:	actinic prurigo Age Factors Case reports Child Children Dermatology Female Humans Immunosuppressive Agents - therapeutic use Life Sciences & Biomedicine Medical treatment Patients Pediatrics photodermatosis photosensitivity Photosensitivity Disorders - drug therapy Pruritus Science & Technology Skin diseases Skin Diseases, Genetic - drug therapy Thalidomide Thalidomide - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Actinic prurigo (AP) is an immune‐mediated photodermatosis that usually starts in childhood and is predominant among American indigenous and mestizo communities. In adults with AP, thalidomide is the treatment of choice; however, there is little information on its use in pediatric patients. We report the case of a 10‐year‐old girl with AP treated successfully with thalidomide.
ISSN:	0736-8046 1525-1470
DOI:	10.1111/pde.14086